All patients
subjects at risk
hydroxychloroquine in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
0.80 [0.52 ; 1.24 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable deathsdetailed results Gonzalez (HCQ), 2020 0.33 [0.06; 1.78]
HYCOVID, 2020 0.54 [0.21; 1.40]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
ORCHID, 2020 1.07 [0.54; 2.11]
TEACH, 2020 1.07 [0.34; 3.37]
0.81 [0.59 ; 1.12 ] Gonzalez (HCQ), 2020, HYCOVID, 2020, HYDRA (Hernandez-Cardenas), 2021, ORCHID, 2020, TEACH, 2020 5 0% 1,138 moderate not evaluable deaths (time to event analysis only)detailed results HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
0.80 [0.52 ; 1.24 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable clinical deteriorationdetailed results TEACH, 2020 1.80 [0.62; 5.21]
1.80 [0.62 ; 5.21 ] TEACH, 2020 1 0% 128 NA not evaluable clinical improvementdetailed results ORCHID, 2020 1.02 [0.73; 1.42]
1.02 [0.73 ; 1.42 ] ORCHID, 2020 1 0% 479 NA not evaluable clinical improvement (14-day)detailed results ORCHID, 2020 1.02 [0.73; 1.42]
1.02 [0.73 ; 1.42 ] ORCHID, 2020 1 0% 479 NA not evaluable clinical improvement (28-day)detailed results ORCHID, 2020 0.97 [0.69; 1.37]
0.97 [0.69 ; 1.37 ] ORCHID, 2020 1 0% 479 NA not evaluable clinical improvement (7-day)detailed results ORCHID, 2020 1.16 [0.84; 1.61]
1.16 [0.84 ; 1.61 ] ORCHID, 2020 1 0% 479 NA not evaluable clinical improvement (time to event analysis only)detailed results HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48]
ORCHID, 2020 0.97 [0.69; 1.36]
1.01 [0.79 ; 1.28 ] HYDRA (Hernandez-Cardenas), 2021, ORCHID, 2020 2 0% 693 low not evaluable death or ventilationdetailed results Gonzalez (HCQ), 2020 0.69 [0.22; 2.21]
HYCOVID, 2020 1.12 [0.45; 2.79]
ORCHID, 2020 1.13 [0.60; 2.13]
1.04 [0.64 ; 1.67 ] Gonzalez (HCQ), 2020, HYCOVID, 2020, ORCHID, 2020 3 0% 794 low not evaluable hospital dischargedetailed results Gonzalez (HCQ), 2020 1.38 [0.46; 4.16]
HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42]
1.04 [0.75 ; 1.44 ] Gonzalez (HCQ), 2020, HYDRA (Hernandez-Cardenas), 2021 2 0% 284 moderate not evaluable off oxygenationdetailed results HYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51]
0.98 [0.64 ; 1.51 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable serious adverse eventsdetailed results ORCHID, 2020 1.26 [0.56; 2.84]
1.26 [0.56 ; 2.84 ] ORCHID, 2020 1 0% 479 NA not evaluable adverse eventsdetailed results ORCHID, 2020 1.42 [0.87; 2.34]
TEACH, 2020 1.16 [0.55; 2.42]
1.33 [0.88 ; 2.01 ] ORCHID, 2020, TEACH, 2020 2 0% 607 low not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-24 07:26 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 657,832
- roots T: 290
